CoChat

Next‐generation sequencing improves treatment efficacy and reduces hospitalization in children with drug‐resistant epilepsy

Open access
Peng, Jing, Pang, Nan, Wang, Ying, Wang, Xiao‐Le, Chen, Jian, Xiong, Juan, Peng, Pan, Zhu, Can‐Hui, Kessi, Miriam Barakael, He, Fang, Yin, Fei · 2019 · CNS Neuroscience & Therapeutics
Cited by 63

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Summary: Background: The purposes of this study were three‐fold: (i) to determine the contribution of known genes to the causation of a broad‐spectrum of pediatric drug‐resistant epilepsy ( DRE ), (ii) to compare the diagnostic yield and cost among different next‐generation sequencing ( NGS ) approaches, and especially (iii) to assess how NGS approaches can benefit patients by improving diagnosis and treatment efficiency. Methods: This study enrolled 273 pediatric DRE patients with no obvious acquired etiology. Seventy‐four patients underwent whole‐exome sequencing ( WES ), 141 patients had epilepsy‐related gene panel testing, and another 58 patients had clinical WES gene panel testing. We obtained these patients’ seizure and hospitalization frequency by periodic follow‐up phone calls and outpatient visits. Results: Genetic diagnosis was achieved in 86 patients (31.5%) and involved 93 likely disease‐causing mutations in 33 genes. In this study, the detection rates of the epilepsy‐related gene panel, the clinical WES gene panel, and WES were 32.6% (46/141), 44.8% (26/58), and 17.3% (13/74), respectively. Moreover, 34 patients accepted corrective therapy according to their mutant genes, after which 52.9% (18/34) became seizure‐free and 38.2% (13/34) achieved seizure reduction. In the end, patients with either positive or negative genetic results had significantly fewer hospitalization incidents (times/half year) than before (positive genetic results group 0.58 ± 1.14 vs 0.10 ± 0.26; negative genetic results group 0.72 ± 1.65 vs 0.12 ± 0.33). Conclusions: These results offer further proof that NGS approaches represent powerful tools for establishing a definitive diagnosis. Moreover, this study indicated how NGS can improve treatment efficacy and reduce hospitalization in children with DRE .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cns.12869

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 63

Metadata

Authors
Peng, J., Pang, N., Wang, Y., Wang, X., Chen, J., Xiong, J., Peng, P., Zhu, C., Kessi, M. B., He, F., & Yin, F.
Venue
CNS Neuroscience & Therapeutics
Publisher
Wiley
Published
2018-06-22
Volume
25
Issue
1
Pages
14-20
ISSN
  • 1755-5930 (ISSN-L)
  • 1755-5949
OpenAlex
W2809436956
Cited by
63
References
1
FWCI
4.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.